Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer
Conclusion: Injections of 99mTc-ADAPT6 are safe and associated with low absorbed and effective doses. A protein dose of 500 μg is preferable for discrimination between tumors with high and low expression of HER2. Further studies are justified to evaluate whether 99mTc-ADAPT6 can be used as an imaging probe to stratify patients for HER2-targeting therapy in areas where PET imaging is not readily available.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Bragina, O., von Witting, E., Garousi, J., Zelchan, R., Sandstrom, M., Orlova, A., Medvedeva, A., Doroshenko, A., Vorobyeva, A., Lindbo, S., Borin, J., Tarabanovskaya, N., Sorensen, J., Hober, S., Chernov, V., Tolmachev, V. Tags: Clinical Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Gastroenterology | HER2 | Liver | Nuclear Medicine | SPECT | Study | Urology & Nephrology